FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155087576> ?p ?o ?g. }

• W2155087576 endingPage "985" @default.
• W2155087576 startingPage "985" @default.
• W2155087576 abstract "To evaluate the efficacy and safety of high-dose tacrine hydrochloride over 30 weeks in patients with probable Alzheimer's disease.A 30-week randomized, double-blind, placebo-controlled, parallel-group trial.Outpatients at 33 US centers.Men and women at least 50 years of age with mild to moderate Alzheimer's disease and otherwise in good health.Group 1 received placebo; group 2 received 40 mg/d of tacrine for 6 weeks, then 80 mg/d for 24 weeks; groups 3 and 4 received 40 mg/d of tacrine for 6 weeks, 80 mg/d for 6 weeks, and 120 mg/d for 6 weeks. Group 3 remained on a dosage of 120 mg/d for a total of 18 weeks; after 6 weeks at 120 mg/d, group 4 titrated to 160 mg/d for the last 12 weeks.Clinician Interview-Based Impression (CIBI), Alzheimer's Disease Assessment Scale--Cognitive subscale (ADAS-Cog), and Final Comprehensive Consensus Assessment (FCCA).A total of 663 patients entered the study; 653 patients were included in an intent-to-treat (ITT) analysis; 263 had evaluable data at 30 weeks. The results of the ITT analysis revealed significant (P < or = .05) dose-response trends and between-group comparisons on CIBI and ADAS-Cog. In evaluable patients, significant dose-response trends were observed for all three primary measures (P < or = .001). Significant differences in favor of 160 mg/d of tacrine vs placebo were observed on the CIBI (P < or = .002) and ADAS-Cog and FCCA (P < or = .001), as well as caregiver-global and quality-of-life assessments (P < or = .05). On the CIBI, 23% and 42% of tacrine-treated patients in the ITT and evaluable-patient populations, respectively, were rated improved compared with 17% and 18% of placebo patients, respectively. The primary reasons for withdrawal of tacrine-treated patients were asymptomatic liver transaminase elevations (28%) and gastrointestinal complaints (16%). These adverse events were reversible on discontinuation of treatment, and many patients were able to restart tacrine.Tacrine produced statistically significant, dose-related improvements on objective performance-based tests, clinician- and caregiver-rated global evaluations, and measures of quality of life. There was no evidence that the large number of patient withdrawals biased the overall conclusions of the study." @default.
• W2155087576 created "2016-06-24" @default.
• W2155087576 creator A5008043878 @default.
• W2155087576 creator A5028453258 @default.
• W2155087576 creator A5051101795 @default.
• W2155087576 creator A5059027860 @default.
• W2155087576 creator A5080144468 @default.
• W2155087576 creator A5085618842 @default.
• W2155087576 date "1994-04-06" @default.
• W2155087576 modified "2023-09-27" @default.
• W2155087576 title "A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease" @default.
• W2155087576 cites W10553127 @default.
• W2155087576 cites W1644143258 @default.
• W2155087576 cites W1847168837 @default.
• W2155087576 cites W1953027527 @default.
• W2155087576 cites W1966795370 @default.
• W2155087576 cites W1972300483 @default.
• W2155087576 cites W1979986969 @default.
• W2155087576 cites W1982064952 @default.
• W2155087576 cites W1982531158 @default.
• W2155087576 cites W1991656070 @default.
• W2155087576 cites W1997696981 @default.
• W2155087576 cites W2009329257 @default.
• W2155087576 cites W2010120109 @default.
• W2155087576 cites W2014937506 @default.
• W2155087576 cites W2020961258 @default.
• W2155087576 cites W2062002803 @default.
• W2155087576 cites W2064691186 @default.
• W2155087576 cites W2080956345 @default.
• W2155087576 cites W2104227586 @default.
• W2155087576 cites W2110765139 @default.
• W2155087576 cites W2128529067 @default.
• W2155087576 cites W2156220037 @default.
• W2155087576 cites W2187766730 @default.
• W2155087576 cites W2314133009 @default.
• W2155087576 cites W2466124716 @default.
• W2155087576 cites W1987621030 @default.
• W2155087576 doi "https://doi.org/10.1001/jama.1994.03510370037029" @default.
• W2155087576 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8139083" @default.
• W2155087576 hasPublicationYear "1994" @default.
• W2155087576 type Work @default.
• W2155087576 sameAs 2155087576 @default.
• W2155087576 citedByCount "773" @default.
• W2155087576 countsByYear W21550875762012 @default.
• W2155087576 countsByYear W21550875762013 @default.
• W2155087576 countsByYear W21550875762014 @default.
• W2155087576 countsByYear W21550875762015 @default.
• W2155087576 countsByYear W21550875762016 @default.
• W2155087576 countsByYear W21550875762017 @default.
• W2155087576 countsByYear W21550875762018 @default.
• W2155087576 countsByYear W21550875762019 @default.
• W2155087576 countsByYear W21550875762020 @default.
• W2155087576 countsByYear W21550875762021 @default.
• W2155087576 countsByYear W21550875762022 @default.
• W2155087576 countsByYear W21550875762023 @default.
• W2155087576 crossrefType "journal-article" @default.
• W2155087576 hasAuthorship W2155087576A5008043878 @default.
• W2155087576 hasAuthorship W2155087576A5028453258 @default.
• W2155087576 hasAuthorship W2155087576A5051101795 @default.
• W2155087576 hasAuthorship W2155087576A5059027860 @default.
• W2155087576 hasAuthorship W2155087576A5080144468 @default.
• W2155087576 hasAuthorship W2155087576A5085618842 @default.
• W2155087576 hasConcept C126322002 @default.
• W2155087576 hasConcept C142724271 @default.
• W2155087576 hasConcept C168563851 @default.
• W2155087576 hasConcept C181199279 @default.
• W2155087576 hasConcept C185592680 @default.
• W2155087576 hasConcept C197934379 @default.
• W2155087576 hasConcept C204243189 @default.
• W2155087576 hasConcept C204787440 @default.
• W2155087576 hasConcept C27081682 @default.
• W2155087576 hasConcept C2776000289 @default.
• W2155087576 hasConcept C2778816929 @default.
• W2155087576 hasConcept C2779046751 @default.
• W2155087576 hasConcept C55493867 @default.
• W2155087576 hasConcept C71924100 @default.
• W2155087576 hasConcept C90924648 @default.
• W2155087576 hasConceptScore W2155087576C126322002 @default.
• W2155087576 hasConceptScore W2155087576C142724271 @default.
• W2155087576 hasConceptScore W2155087576C168563851 @default.
• W2155087576 hasConceptScore W2155087576C181199279 @default.
• W2155087576 hasConceptScore W2155087576C185592680 @default.
• W2155087576 hasConceptScore W2155087576C197934379 @default.
• W2155087576 hasConceptScore W2155087576C204243189 @default.
• W2155087576 hasConceptScore W2155087576C204787440 @default.
• W2155087576 hasConceptScore W2155087576C27081682 @default.
• W2155087576 hasConceptScore W2155087576C2776000289 @default.
• W2155087576 hasConceptScore W2155087576C2778816929 @default.
• W2155087576 hasConceptScore W2155087576C2779046751 @default.
• W2155087576 hasConceptScore W2155087576C55493867 @default.
• W2155087576 hasConceptScore W2155087576C71924100 @default.
• W2155087576 hasConceptScore W2155087576C90924648 @default.
• W2155087576 hasIssue "13" @default.
• W2155087576 hasLocation W21550875761 @default.
• W2155087576 hasLocation W21550875762 @default.
• W2155087576 hasOpenAccess W2155087576 @default.
• W2155087576 hasPrimaryLocation W21550875761 @default.
• W2155087576 hasRelatedWork W1970126290 @default.

• next